Metformin and cancer

Abe, 2008, AGE-RAGE system and carcinogenesis, Curr. Pharm. Des., 14, 940, 10.2174/138161208784139765 Algire, 2012, Metformin reduces endogenous reactive oxygen species and associated DNA damage, Cancer Prev. Res. (Phila), 5, 536, 10.1158/1940-6207.CAPR-11-0536 Ashinuma, 2012, Antiproliferative action of metformin in human lung cancer cell lines, Oncol. Rep., 28, 8 Azoulay, 2011, Metformin and the incidence of prostate cancer in patients with type 2 diabetes, Cancer Epidemiol. Biomarkers Prev., 20, 337, 10.1158/1055-9965.EPI-10-0940 Barone, 2008, Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis, JAMA-J. Am. Med. Assoc., 300, 2754, 10.1001/jama.2008.824 Barone, 2010, Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis, Diabetes Care, 33, 931, 10.2337/dc09-1721 Belfiore, 2011, Insulin receptor and cancer, Endocrinol. Relat. Cancer, 18, R125, 10.1530/ERC-11-0074 Betancourt-Albrecht, 2003, Hypogonadism and diabetes, Int. J. Impotence Res., 15, S14, 10.1038/sj.ijir.3901031 Bhalla, 2012, Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis, Cancer Prev. Res. (Phila), 5, 544, 10.1158/1940-6207.CAPR-11-0228 Bodmer, 2012, Metformin does not alter the risk of lung cancer: a case-control analysis, Lung Cancer, 78, 133, 10.1016/j.lungcan.2012.08.010 Bodmer, 2011, Use of metformin and the risk of ovarian cancer: a case-control analysis, Gynecol. Oncol., 123, 200, 10.1016/j.ygyno.2011.06.038 Bodmer, 2012, Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis, Cancer Epidemiol. Biomarkers Prev., 21, 280, 10.1158/1055-9965.EPI-11-0992-T Bodmer, 2010, Long-term metformin use is associated with decreased risk of breast cancer, Diabetes Care, 33, 1304, 10.2337/dc09-1791 Bonanni, 2012, Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial, J. Clin. Oncol., 30, 2593, 10.1200/JCO.2011.39.3769 Bowker, 2006, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin, Diabetes Care, 29, 254, 10.2337/diacare.29.02.06.dc05-1558 Bowker, 2011, Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women, Diabetes Care, 34, 2542, 10.2337/dc11-1199 Boyle, 2012, Diabetes and breast cancer risk: a meta-analysis, Br. J. Cancer, 107, 1608, 10.1038/bjc.2012.414 Byrne, 2012, Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management, Diabetic Med., 29, 1098, 10.1111/j.1464-5491.2012.03732.x Cantrell, 2010, Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy, Gynecol. Oncol., 116, 92, 10.1016/j.ygyno.2009.09.024 Caronia, 1999, Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection, Hepatology, 30, 1059, 10.1002/hep.510300416 Carstensen, 2012, Cancer occurrence in Danish diabetic patients: duration and insulin effects, Diabetologia, 55, 948, 10.1007/s00125-011-2381-4 Chen, 2006, Seroprevalence of hepatitis B and C in type 2 diabetic patients, J. Chin. Med. Assoc., 69, 146, 10.1016/S1726-4901(09)70195-9 Chlebowski, 2012, Diabetes, metformin, and breast cancer in postmenopausal women, J. Clin. Oncol., 30, 2844, 10.1200/JCO.2011.39.7505 Chowdhury, 2010, Diabetes and cancer, QJM, 103, 905, 10.1093/qjmed/hcq149 Chung, 2008, Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea, Dis. Colon Rectum, 51, 593, 10.1007/s10350-007-9184-1 Col, 2012, Metformin and breast cancer risk: a meta-analysis and critical literature review, Breast Cancer Res. Treat., 135, 639, 10.1007/s10549-012-2170-x Cowie, 2006, Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002, Diabetes Care, 29, 1263, 10.2337/dc06-0062 Cufi, 2012, Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts, Oncotarget, 3, 395, 10.18632/oncotarget.488 Currie, 2009, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia, 52, 1766, 10.1007/s00125-009-1440-6 Currie, 2012, Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival, Diabetes Care, 35, 299, 10.2337/dc11-1313 Cusi, 1996, Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus, J. Clin. Endocrinol. Metab., 81, 4059 Cusi, 2000, Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle, J. Clin. Invest., 105, 311, 10.1172/JCI7535 Dancey, 2010, mTOR signaling and drug development in cancer, Nat. Rev. Clin. Oncol., 7, 209, 10.1038/nrclinonc.2010.21 Davies, 1995, 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC, FEBS Lett., 377, 421, 10.1016/0014-5793(95)01368-7 Davila, 2005, Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study, Gut, 54, 533, 10.1136/gut.2004.052167 DeFronzo, 1995, Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group, N. Engl. J. Med., 333, 541, 10.1056/NEJM199508313330902 Diabetes Prevention Program Research Group, 2012, Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study, Diabetes Care, 35, 731, 10.2337/dc11-1299 Donadon, 2010, Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease, Liver Int., 30, 750, 10.1111/j.1478-3231.2010.02223.x Dong, 2012, Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression, J. Obstet. Gynaecol. Res., 38, 1077, 10.1111/j.1447-0756.2011.01839.x Dowling, 2012, Metformin in cancer: translational challenges, J. Mol. Endocrinol., 48, R31, 10.1530/JME-12-0007 Dowling, 2007, Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells, Cancer Res., 67, 10804, 10.1158/0008-5472.CAN-07-2310 El-Mir, 2000, Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I, J. Biol. Chem., 275, 223, 10.1074/jbc.275.1.223 El-Serag, 2006, The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence, Clin. Gastroenterol. Hepatol., 4, 369, 10.1016/j.cgh.2005.12.007 Engelman, 2010, Chemoprevention meets glucose control, Cancer Prev. Res. (Phila), 3, 1049, 10.1158/1940-6207.CAPR-10-0178 Everhart, 1995, Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis, JAMA: J. Am. Med. Assoc., 273, 1605, 10.1001/jama.1995.03520440059037 Foretz, 2010, Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state, J. Clin. Invest., 120, 2355, 10.1172/JCI40671 Frasca, 2008, The role of insulin receptors and IGF-I receptors in cancer and other diseases, Arch. Physiol. Biochem., 114, 23, 10.1080/13813450801969715 Friberg, 2007, Diabetes mellitus and risk of endometrial cancer: a meta-analysis, Diabetologia, 50, 1365, 10.1007/s00125-007-0681-5 Garrett, 2012, Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer, Br. J. Cancer, 106, 1374, 10.1038/bjc.2012.71 Geraldine, 2012, Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting, Diabetes Res. Clin. Pract., 97, 331, 10.1016/j.diabres.2012.02.002 Giovannucci, 2010, Diabetes and cancer: a consensus report, CA Cancer J. Clin., 60, 207, 10.3322/caac.20078 Gonzalez-Angulo, 2010, Metformin: a therapeutic opportunity in breast cancer, Clin. Cancer Res., 16, 1695, 10.1158/1078-0432.CCR-09-1805 Goodwin, 2011, Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents, Breast Cancer Res. Treat., 126, 215, 10.1007/s10549-010-1224-1 Green, 2010, The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation, Blood, 116, 4262, 10.1182/blood-2010-02-269837 Guppy, 2011, Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer, Future Oncol., 7, 727, 10.2217/fon.11.49 Hadad, 2011, Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial, Breast Cancer Res. Treat., 128, 783, 10.1007/s10549-011-1612-1 Hanna, 2012, Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway, Gynecol. Oncol., 125, 458, 10.1016/j.ygyno.2012.01.009 Hardie, 2004, The AMP-activated protein kinase pathway—new players upstream and downstream, J. Cell Sci., 117, 5479, 10.1242/jcs.01540 Harris, 1998, Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994, Diabetes Care, 21, 518, 10.2337/diacare.21.4.518 Harris, 2004, The chemical pathology of insulin resistance and the metabolic syndrome, MLO: Med. Lab. Obs., 36, 22 Hassan, 2010, Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma, Cancer, 116, 1938, 10.1002/cncr.24982 Hawley, 1996, Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase, J. Biol. Chem., 271, 27879, 10.1074/jbc.271.44.27879 He, 2012, Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer, Ann. Oncol., 23, 1771, 10.1093/annonc/mdr534 Higurashi, 2012, Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial, BMC Cancer, 12, 118, 10.1186/1471-2407-12-118 Ho, 2008, Evaluating the evidence: is there a rigid hierarchy?, Circulation, 118, 1675, 10.1161/CIRCULATIONAHA.107.721357 Hosono, 2010, Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial, Cancer Prev. Res. (Phila), 3, 1077, 10.1158/1940-6207.CAPR-10-0186 Huai, 2012, Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway, Biochem. Biophys. Res. Commun., 422, 398, 10.1016/j.bbrc.2012.05.001 Hurst, 2003, Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management, Ann. Intern. Med., 139, 824, 10.7326/0003-4819-139-10-200311180-00010 Ikeda, 2000, Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine, Biochem. Pharmacol., 59, 887, 10.1016/S0006-2952(99)00396-2 Iliopoulos, 2011, Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types, Cancer Res., 71, 3196, 10.1158/0008-5472.CAN-10-3471 Jiang, 1999, Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats, J. Clin. Invest., 104, 447, 10.1172/JCI5971 Kalender, 2010, Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner, Cell Metab., 11, 390, 10.1016/j.cmet.2010.03.014 Kasper, 2006, A meta-analysis of diabetes mellitus and the risk of prostate cancer, Cancer Epidemiol. Biomarkers Prev., 15, 2056, 10.1158/1055-9965.EPI-06-0410 Kato, 2012, The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo, Mol. Cancer Ther., 11, 549, 10.1158/1535-7163.MCT-11-0594 King, 1998, Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections, Diabetes Care, 21, 1414, 10.2337/diacare.21.9.1414 Klubo-Gwiezdzinska, 2012, Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells, Endocrinol. Relat. Cancer, 19, 447, 10.1530/ERC-12-0046 Klumpen, 2010, Inhibitors of mTOR, Oncologist, 15, 1262, 10.1634/theoncologist.2010-0196 Knowler, 2009, 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study, Lancet, 374, 1677, 10.1016/S0140-6736(09)61457-4 Lai, 2012, Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study, Am. J. Gastroenterol., 107, 46, 10.1038/ajg.2011.384 Lai, 2012, Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan, Clin Lung Cancer, 13, 143, 10.1016/j.cllc.2011.10.002 Landman, 2010, Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16, Diabetes Care, 33, 322, 10.2337/dc09-1380 Larsson, 2005, Diabetes mellitus and risk of colorectal cancer: a meta-analysis, J. Nat. Cancer Inst., 97, 1679, 10.1093/jnci/dji375 Larsson, 2011, Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies, Diabetologia, 54, 1013, 10.1007/s00125-011-2051-6 Lee, 2011, Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals, BMC Cancer, 11, 20, 10.1186/1471-2407-11-20 Lehman, 2012, Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients, Diabetes Care, 35, 1002, 10.2337/dc11-1829 Lewis, 2007, Medical therapy for diabetes is associated with increased use of lower endoscopy, Pharmacoepidemiol. Drug Saf., 16, 1195, 10.1002/pds.1441 Liao, 2011, Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature, Asian Pac. J. Cancer Prev., 12, 1061 Libby, 2009, New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes, Diabetes Care, 32, 1620, 10.2337/dc08-2175 Lipscombe, 2008, The impact of diabetes on survival following breast cancer, Breast Cancer Res. Treat., 109, 389, 10.1007/s10549-007-9654-0 Lipscombe, 2007, Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study, Lancet, 369, 750, 10.1016/S0140-6736(07)60361-4 Liu, 2012, Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro, Anticancer Res., 32, 1627 Lonardo, 2009, Hepatitis C and diabetes: the inevitable coincidence?, Expert Rev. Anti Infect. Ther., 7, 293, 10.1586/eri.09.3 Ma, 2008, Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis, Lancet Oncol., 9, 1039, 10.1016/S1470-2045(08)70235-3 MacKenzie, 2011, Diabetes and risk of bladder cancer: evidence from a case-control study in New England, Cancer, 117, 1552, 10.1002/cncr.25641 Mazzone, 2012, The effect of metformin and thiazolidinedione use on lung cancer in diabetics, BMC Cancer, 12, 410, 10.1186/1471-2407-12-410 Memmott, 2009, LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin, J. Clin. Oncol., 27, 10.1200/JCO.2009.25.3963 Menendez, 2007, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, Nat. Rev. Cancer, 7, 763, 10.1038/nrc2222 Meyerhardt, 2003, Impact of diabetes mellitus on outcomes in patients with colon cancer, J. Clin. Oncol., 21, 433, 10.1200/JCO.2003.07.125 Michels, 2003, Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study, Diabetes Care, 26, 1752, 10.2337/diacare.26.6.1752 Miyazaki, 2002, Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes, Diabetes Care, 25, 517, 10.2337/diacare.25.3.517 Niraula, 2012, Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study, Breast Cancer Res. Treat., 135, 821, 10.1007/s10549-012-2223-1 Nkontchou, 2011, Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients, J. Clin. Endocrinol. Metab., 96, 2601, 10.1210/jc.2010-2415 Noble, 2006, Meta-analysis: methods, strengths, weaknesses, and political uses, J. Lab. Clin. Med., 147, 7, 10.1016/j.lab.2005.08.006 Noto, 2012, Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis, PLoS One, 7, e33411, 10.1371/journal.pone.0033411 Okumura, 2010, Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs, J. Gastroenterol., 45, 1097, 10.1007/s00535-010-0310-9 Pandey, 2011, Diabetes mellitus and the risk of cancer, Minerva Endocrinol., 36, 187 Pisani, 2008, Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies, Arch. Physiol. Biochem., 114, 63, 10.1080/13813450801954451 Pollak, 2008, Insulin and insulin-like growth factor signalling in neoplasia, Nat. Rev. Cancer, 8, 915, 10.1038/nrc2536 Pollak, 2012, The insulin and insulin-like growth factor receptor family in neoplasia: an update, Nat. Rev. Cancer, 12, 159, 10.1038/nrc3215 Pollak, 2012, Investigating metformin for cancer prevention and treatment: the end of the beginning, Cancer Discov., 2, 778, 10.1158/2159-8290.CD-12-0263 Postic, 2008, The role of the lipogenic pathway in the development of hepatic steatosis, Diabetes Metab., 34, 643, 10.1016/S1262-3636(08)74599-3 Qu, 2012, In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma, Hepatol. Res. Off. J. Jpn. Soc. Hepatol., 42, 922, 10.1111/j.1872-034X.2012.01007.x Rattan, 2011, Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo, Neoplasia, 13, 483, 10.1593/neo.11148 Reilly, 2012, Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus, J. Diabetes Sci. Technol., 6, 858, 10.1177/193229681200600417 Richardson, 2005, Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer, Nat. Clin. Pract. Oncol., 2, 48, 10.1038/ncponc0062 Rizos, 2009, How safe is the use of thiazolidinediones in clinical practice?, Expert Opin. Drug Saf., 8, 15, 10.1517/14740330802597821 Rizos, 2008, Pleiotropic effects of thiazolidinediones, Expert Opin. Pharmacother., 9, 1087, 10.1517/14656566.9.7.1087 Romero, 2012, Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity, Obstet. Gynecol., 119, 61, 10.1097/AOG.0b013e3182393ab3 Roper, 2001, Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study, BMJ, 322, 1389, 10.1136/bmj.322.7299.1389 Ruiter, 2012, Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study, Diabetes Care, 35, 119, 10.2337/dc11-0857 Sadeghi, 2012, Metformin use is associated with better survival of diabetic patients with pancreatic cancer, Clin. Cancer Res., 18, 2905, 10.1158/1078-0432.CCR-11-2994 Salpeter, 2010, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, Cochrane Database Syst. Rev., CD002967 Samani, 2007, The role of the IGF system in cancer growth and metastasis: overview and recent insights, Endocrinol. Rev., 28, 20, 10.1210/er.2006-0001 Shaw, 2004, The LKB1 tumor suppressor negatively regulates mTOR signaling, Cancer Cell, 6, 91, 10.1016/j.ccr.2004.06.007 Sikka, 2012, Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation, Cell Cycle, 11, 1374, 10.4161/cc.19798 Skinner, 2012, Metformin use and improved response to therapy in esophageal adenocarcinoma, Acta Oncol. Smiechowski, 2012, The use of metformin and the incidence of lung cancer in patients with type 2 diabetes, Diabetes Care Song, 2012, Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells, Sci. Rep., 2, 362, 10.1038/srep00362 Soranna, 2012, Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis, Oncologist, 17, 813, 10.1634/theoncologist.2011-0462 Stevens, 2012, Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials, Diabetologia, 55, 2593, 10.1007/s00125-012-2653-7 Stevens, 2012, Erratum to: cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials, Diabetologia, 55, 3399, 10.1007/s00125-012-2740-9 Suissa, 2012, Metformin and the risk of cancer: time-related biases in observational studies, Diabetes care, 35, 2665, 10.2337/dc12-0788 Tan, 2011, Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells, J. Clin. Endocrinol. Metab., 96, 808, 10.1210/jc.2010-1803 Tseng, 2012, Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan, Eur. J. Endocrinol., 167, 409, 10.1530/EJE-12-0369 van Staa, 2012, Glucose-lowering agents and the patterns of risk for cancer: a study with the general practice research database and secondary care data, Diabetologia, 55, 654, 10.1007/s00125-011-2390-3 Vigneri, 2009, Diabetes and cancer, Endocrinol. Relat. Cancer, 16, 1103, 10.1677/ERC-09-0087 Walker, 2008, Meta-analysis: its strengths and limitations, Cleve. Clin. J. Med., 75, 431, 10.3949/ccjm.75.6.431 Wei, 2009, PPARgamma-independent antitumor effects of thiazolidinediones, Cancer Lett., 276, 119, 10.1016/j.canlet.2008.08.008 Wilcock, 1991, Reconsideration of inhibitory effect of metformin on intestinal glucose absorption, J. Pharm. Pharmacol., 43, 120, 10.1111/j.2042-7158.1991.tb06645.x Wright, 2006, Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73, J. Diabetes Complications, 20, 395, 10.1016/j.jdiacomp.2005.08.010 Wright, 2009, Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study, Cancer Causes Control, 20, 1617, 10.1007/s10552-009-9407-y Wu, 2011, Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153, Neoplasma, 58, 482, 10.4149/neo_2011_06_482 Wysocki, 2010, Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin, Expert Rev. Mol. Diagn., 10, 509, 10.1586/erm.10.22 Yang, 2004, Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients, Gastroenterology, 127, 1044, 10.1053/j.gastro.2004.07.011 Yoon, 2006, Epidemic obesity and type 2 diabetes in Asia, Lancet, 368, 1681, 10.1016/S0140-6736(06)69703-1 Zhang, 2011, Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis, Diabetes Care, 34, 2323, 10.2337/dc11-0512 Zhang, 2012, Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis, J. Clin. Endocrinol. Metab., 97, 2347, 10.1210/jc.2012-1267